Cargando…
164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
BACKGROUND: Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with st...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677511/ http://dx.doi.org/10.1093/ofid/ofad500.237 |
_version_ | 1785150147268706304 |
---|---|
author | Thomas, Jenni Clark, Justin A Arora, Vaneet Burgess, David Burgess, Donna R Mynatt, Ryan VanHoose, Jeremy Wallace, Katie L Cotner, Sarah |
author_facet | Thomas, Jenni Clark, Justin A Arora, Vaneet Burgess, David Burgess, Donna R Mynatt, Ryan VanHoose, Jeremy Wallace, Katie L Cotner, Sarah |
author_sort | Thomas, Jenni |
collection | PubMed |
description | BACKGROUND: Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with standard microbiologic identification methods and concordance of ePlex® genotypic resistance mechanism detection and standard susceptibility testing. Secondary outcomes included panel specific performance and characterization of antimicrobial stewardship opportunities. METHODS: This retrospective, single center study included patients with a positive blood culture from May 2020 – January 2021. Polymicrobial cultures were excluded. Identification concordance was evaluated between ePlex® and MALDI-TOF, BD Phoenix™, and biochemical tests. Resistance mechanism/phenotypic susceptibility concordance was evaluated between ePlex® and BD Phoenix(TM)/ETEST®. MecA was assessed via oxacillin resistance, vanA via vancomycin resistance, CTX-M via ceftriaxone resistance, and KPC via carbapenem resistance. Opportunities for antimicrobial stewardship were also quantified. RESULTS: The overall identification concordance rate in 1276 positive blood cultures was 98.2%, with rates of 98.5%, 98.1%, and 93.3% for Gram-positive, Gram-negative, and fungal isolates, respectively. In 381 staphylococcal isolates, concordance rates were 98.3% and 100% for the presence and absence of mecA. Both the presence and absence of vanA were 100% concordant in 63 enterococcal isolates. CTX-M and KPC were evaluated in 189 Enterobacterales. Concordance rates were 96.8% for the presence of CTX-M and 60% for the presence of KPC, demonstrating that 40% of carbapenem resistance was due to non-enzymatic mechanisms. Ceftriaxone and carbapenem susceptibility correlated with the absence of CTX-M and KPC, respectively, in 100% of cultures. A majority of ePlex results (69.5%) represented opportunities for potential antimicrobial stewardship intervention. CONCLUSION: High concordance rates between ePlex® and standard identification and susceptibility testing methods enable rapid antimicrobial optimization. Numerous opportunities for antimicrobial stewardship were identified based on ePlex® results. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10677511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106775112023-11-27 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities Thomas, Jenni Clark, Justin A Arora, Vaneet Burgess, David Burgess, Donna R Mynatt, Ryan VanHoose, Jeremy Wallace, Katie L Cotner, Sarah Open Forum Infect Dis Abstract BACKGROUND: Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with standard microbiologic identification methods and concordance of ePlex® genotypic resistance mechanism detection and standard susceptibility testing. Secondary outcomes included panel specific performance and characterization of antimicrobial stewardship opportunities. METHODS: This retrospective, single center study included patients with a positive blood culture from May 2020 – January 2021. Polymicrobial cultures were excluded. Identification concordance was evaluated between ePlex® and MALDI-TOF, BD Phoenix™, and biochemical tests. Resistance mechanism/phenotypic susceptibility concordance was evaluated between ePlex® and BD Phoenix(TM)/ETEST®. MecA was assessed via oxacillin resistance, vanA via vancomycin resistance, CTX-M via ceftriaxone resistance, and KPC via carbapenem resistance. Opportunities for antimicrobial stewardship were also quantified. RESULTS: The overall identification concordance rate in 1276 positive blood cultures was 98.2%, with rates of 98.5%, 98.1%, and 93.3% for Gram-positive, Gram-negative, and fungal isolates, respectively. In 381 staphylococcal isolates, concordance rates were 98.3% and 100% for the presence and absence of mecA. Both the presence and absence of vanA were 100% concordant in 63 enterococcal isolates. CTX-M and KPC were evaluated in 189 Enterobacterales. Concordance rates were 96.8% for the presence of CTX-M and 60% for the presence of KPC, demonstrating that 40% of carbapenem resistance was due to non-enzymatic mechanisms. Ceftriaxone and carbapenem susceptibility correlated with the absence of CTX-M and KPC, respectively, in 100% of cultures. A majority of ePlex results (69.5%) represented opportunities for potential antimicrobial stewardship intervention. CONCLUSION: High concordance rates between ePlex® and standard identification and susceptibility testing methods enable rapid antimicrobial optimization. Numerous opportunities for antimicrobial stewardship were identified based on ePlex® results. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677511/ http://dx.doi.org/10.1093/ofid/ofad500.237 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Thomas, Jenni Clark, Justin A Arora, Vaneet Burgess, David Burgess, Donna R Mynatt, Ryan VanHoose, Jeremy Wallace, Katie L Cotner, Sarah 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities |
title | 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities |
title_full | 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities |
title_fullStr | 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities |
title_full_unstemmed | 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities |
title_short | 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities |
title_sort | 164. performance of eplex® blood culture identification panels in clinical isolates and characterization of antimicrobial stewardship opportunities |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677511/ http://dx.doi.org/10.1093/ofid/ofad500.237 |
work_keys_str_mv | AT thomasjenni 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT clarkjustina 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT aroravaneet 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT burgessdavid 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT burgessdonnar 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT mynattryan 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT vanhoosejeremy 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT wallacekatiel 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities AT cotnersarah 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities |